News Releases

  • 12 Jul 2016
    Patheon N.V. ("Patheon" or the "company") today announced the commencement of the initial public offering of 30,487,805 of its ordinary shares. Patheon is selling 25,609,756 ordinary shares and the selling stockholder named in the prospectus is selling 4,878,049 ordinary shares. The current expected initial public offering price is between $19.00 and $22.00 per share. The company has granted the underwriters a 30-day option to purchase up to an additional 4,573,171 ordinary shares from themore...
  • 05 Jul 2016
    Patrick Glaser

    Industry veteran to lead growing business segment for company 

    Patheon, a leading global provider of pharmaceutical development and manufacturing services, announced today that Patrick Glaser was appointed senior vice president of the company’s small molecule active pharmaceutical ingredient (API) business. He will be responsible for leading the transformation and expansion of the company’s API service offering in Europe and North America and will report to Lukas Utiger, president of Patheon’s drug substance services division.Glaser joins Patheon frommore...
  • 31 May 2016

    Brings 20+ Years Global, Operational and Financial Experience to Patheon

    DURHAM, N.C.--(BUSINESS WIRE)--Patheon, the leading global provider of pharmaceutical development and manufacturing services announced today that Michel Lagarde has been appointed as its President, effective immediately. In this newly created role, Lagarde will lead global corporate and cross-enterprise operations and report to Patheon CEO, James Mullen. Mullen will continue to direct the company’s global growth strategy, as well as oversee the Patheon’s business segments,more...